ClearPoint Neuro, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
ClearPoint Neuro, Inc. (CLPT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $12.40 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-03
- ClearPoint Neuro, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $12.40, a 70.49% decline year-over-year.
- ClearPoint Neuro, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $42.02, a 12.53% decline year-over-year.
- ClearPoint Neuro, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $48.04.
- ClearPoint Neuro, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2022-03-31 was $37.68.
- ClearPoint Neuro, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2025 was $32.15, a 21.81% decline from fiscal 2024.
- ClearPoint Neuro, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $41.12, a 22.49% decline from fiscal 2023.
- ClearPoint Neuro, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $53.05, a 22.60% increase from fiscal 2022.
- ClearPoint Neuro, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $43.27, a 127.62% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $12.40 10-Q · filed 2026-08-03 | ||||
| 2026-03-31 | $12.40 10-Q · filed 2026-05-13 | ||||
| 2025-12-31 | $32.15 10-K · filed 2026-03-17 | ||||
| 2025-09-30 | $32.15 10-Q · filed 2025-11-06 | ||||
| 2025-06-30 | $34.78 10-Q · filed 2025-08-12 | ||||
| 2025-03-31 | $42.02 10-Q · filed 2025-05-13 | ||||
| 2024-12-31 | $41.12 10-K · filed 2025-02-26 | ||||
| 2024-09-30 | $42.19 10-Q · filed 2024-11-07 | ||||
| 2024-06-30 | $42.82 10-Q · filed 2024-08-07 | ||||
| 2024-03-31 | $48.04 10-Q · filed 2024-05-07 | ||||
| 2023-12-31 | $53.05 10-K · filed 2024-03-12 | ||||
| 2023-09-30 | $41.52 10-Q · filed 2023-11-09 | ||||
| 2023-06-30 | $39.67 10-Q · filed 2023-08-08 | ||||
| 2022-12-31 | $43.27 10-K · filed 2023-03-01 | ||||
| 2022-09-30 | $43.24 10-Q · filed 2022-11-08 | ||||
| 2022-06-30 | $40.07 10-Q · filed 2022-08-10 | ||||
| 2022-03-31 | $37.68 10-Q · filed 2022-05-11 | ||||
| 2021-12-31 | $19.01 10-K · filed 2022-03-09 | ||||
| 2021-09-30 | $20.46 10-Q · filed 2021-11-10 | ||||
| 2021-06-30 | $20.46 10-Q · filed 2021-08-12 | ||||
| 2020-12-31 | $72.00 10-K · filed 2021-03-22 | ||||
| 2020-03-31 | $3.95 10-Q · filed 2020-05-13 | ||||
| 2019-12-31 | $95.37 10-K · filed 2021-03-22 | ||||
| 2018-12-31 | $18.77 10-K · filed 2020-03-27 | ||||
| 2017-12-31 | $35.74 10-K · filed 2019-04-01 | ||||
| 2016-12-31 | $12.67 10-K · filed 2018-03-21 | ||||
| 2015-12-31 | $59.20 10-K · filed 2017-03-09 | $1.48 10-K · filed 2016-03-25 | |||
| 2014-12-31 | $1.42 10-K · filed 2016-03-25 | ||||
| 2013-12-31 | $4.33 10-K · filed 2015-03-17 | ||||
| 2012-12-31 | $2.14 10-K · filed 2014-03-28 | ||||
| 2011-12-31 | $4.93 10-K/A · filed 2013-08-19 | ||||
| 2010-12-31 | $5.06 10-K/A · filed 2013-08-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sight Sciences, Inc. (SGHT) | United States | $0.478B | -9.95 |
| NeuroPace Inc (NPCE) | United States | $0.480B | -28.52 |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| TACTILE SYSTEMS TECHNOLOGY INC (TCMD) | United States | $0.519B | 27.16 |
| CERUS CORP (CERS) | United States | $0.525B | -86.40 |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| DELCATH SYSTEMS, INC. (DCTH) | United States | $0.558B | 820.33 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |